The nation of Zimbabwe has rejected a major American health deal worth $367m (£272m) spanning five years over Washington's insistence on confidential biological samples.
The decision became public after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government representative later stated that the United States was seeking health data for scientific study and profit while was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued talks to find a deal suitable to both sides so the country's critical HIV programme can proceed.
Broader Implications
This development follows a similar situation in Kenya, where a court suspended a related deal with the US following concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
As per statements, Sixteen nations in Africa have to date agreed to these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no certainty that the end products would be available to our citizens if a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This framework is designed to guarantee that when a country contributes its information, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
These objections over the US deal "are not meant as opposition to America," he added.
"We welcome continued dialogue with our US partners on how future co-operation might be structured in a manner that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that negotiations must proceed since much of the country's Aids initiatives were funded by foreign aid.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group said.
This impasse highlights the ongoing challenges between accepting much-needed foreign assistance and safeguarding local interests in an increasingly interconnected world.